I was suspicious when the Deerfield Lending Agreement was announced that it included a stock conversion option that had such a wide conversion price range $3.33 - $6.67, which obviously will benefit Deerfield more for them to see the stock price decline to the low end. Don't know why they just didn't insist on a specific strike price for a fixed number of shares. Mannkind announced the Deerfield deal on July 1, 2013 when the stock price was close to $8, so why would they include a conversion option for Deerfield that was more than 50% below the current price ? I also was suspicious of the Deerfield Milestone Agreement, which had Mannkind receiving upfront funding of only $18.9 million in exchange for giving away $90 million of the company's future revenues. I believe Mannkind could have done a better financing deal other than the Deerfield Deal and if the strategy was to leverage Deerfield during partnership/buyout talks, I hope the end results justify the deal.
But wait! Didn't MNKD state in their 8k Q&A that Deerfield decided the data met the tranche requirements so all is good with MNKD!?
That wasn't an attempt to pull wool over our eyes was it? MNKD wouldn't do such a thing would they? Their attorney that signed the 8k didn't sell 20k shares the same day it was filed b/c he knew it was BS did he?
He just needed money for his boys college fund, right?
That pretty much settles it - you're an idiot. First with the ridiculous demands for news, now this....the entire BioTech market is getting pounded, imbecile. Mannkind doesn't owe you jack other than an FDA approval and their best attempt to run a good company. Deerfield was a good deal, they needed the money, and we're now financially viable until approval. Your constant whining is annoying, and finally I have to ignore your stupid #$%$..